Advanced Oncotherapy plc

Equities

AVO

GB00BD6SX109

Advanced Medical Equipment & Technology

Market Closed - London S.E. 02:30:00 2023-06-30 am EDT 5-day change 1st Jan Change
1.925 GBX -.--% Intraday chart for Advanced Oncotherapy plc +10.00% +10.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sareum ups retail offer; SThree nabs former ITV exec AN
EARNINGS AND TRADING: Frontier IP sells last of Exscientia holding AN
Advanced Oncotherapy eyes USD15 million tranche in February AN
Advanced Oncotherapy Faces Delay in Receiving $15 Million Funding from Investor MT
Advanced Oncotherapy in advanced talks regarding loan AN
Advanced Oncotherapy in talks over possible cash injection AN
Advanced Oncotherapy Signs Deal with Investor for Potential $80 Million Funding MT
Advanced Oncotherapy results delayed, funding talks continue AN
Advanced Oncotherapy plans to raise up to GBP110 million AN
FTSE 100 Closes Monday Down 0.4% Dragged by Miners DJ
UK Finance Chiefs Are More Gloomy About Outlook DJ
London Stocks Seen Opening Lower DJ
Advanced Oncotherapy Announces Recapitalisation and Funding Plan CI
Jadestone Energy holds production and capex targets AN
FTSE 100 Closes Up 0.8% Lifted by Banks DJ
Market Pricing of BOE's Interest-Rate Rises Seen Excessive DJ
FTSE 100 Rises as UK Economy Avoids Contraction in 1Q DJ
UK June House Price Slip Shows Buyer Pressures DJ
Odey Asset Management Cuts Stake in De La Rue, Advanced Oncotherapy, Others MT
Advanced Oncotherapy Receives Request for Partial Conversion of Notes to Shares MT
Advanced Oncotherapy optimistic of securing further funding AN
Advanced Oncotherapy plc announced that it has received £3.8626 million in funding CI
Online Blockchain keeping ADVFN at "arms length" AN
Advanced Oncotherapy Secures Additional Funds Via Secured Convertible Note MT
Sterling Rises, Seen Driven by Risk Sentiment And Dollar DJ
Chart Advanced Oncotherapy plc
More charts
Advanced Oncotherapy Plc is a United Kingdom-based specialist developer and provider of a proton therapy system, the LIGHT system. The Company’s team, ADAM, based in Geneva, is focused on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control. The linear design of LIGHT allows for active longitudinal modulation along the proton beam axis and the variation of the proton beam by electronic means during cancer treatment. The modular feature of LIGHT offers hospitals and treatment centers the flexibility to customize cancer treatment plans based on a range of energies. Its subsidiaries include ADAM S.A., Advanced Oncotherapy Americas Inc, Advanced Oncotherapy B.V., Advanced Oncotherapy Resources Ltd, APTS Harley Street Ltd, Advanced Oncotherapy (China) Ltd, Advanced Oncotherapy Proton Therapy Services Ltd and other.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. AVO Stock
  4. News Advanced Oncotherapy plc
  5. Advanced Oncotherapy : Secures Financing Deal to 'Democratize' Proton Beam Therapy; Stock Up 5%